Linked Life Data

9526567

Source:http://linkedlifedata.com/resource/pubmed/id/9526567

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9526567rdf:typepubmed:Citationlld:pubmed
pubmed-article:9526567lifeskim:mentionsumls-concept:C0677040lld:lifeskim
pubmed-article:9526567lifeskim:mentionsumls-concept:C1621296lld:lifeskim
pubmed-article:9526567lifeskim:mentionsumls-concept:C0205344lld:lifeskim
pubmed-article:9526567lifeskim:mentionsumls-concept:C2699488lld:lifeskim
pubmed-article:9526567lifeskim:mentionsumls-concept:C0672962lld:lifeskim
pubmed-article:9526567lifeskim:mentionsumls-concept:C0162827lld:lifeskim
pubmed-article:9526567pubmed:issue6lld:pubmed
pubmed-article:9526567pubmed:dateCreated1998-4-16lld:pubmed
pubmed-article:9526567pubmed:abstractText(RS)-2-Amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid (Bu-HIBO, 6) has previously been shown to be an agonist at (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors and an inhibitor of CaCl2-dependent [3H]-(S)-glutamic acid binding (J. Med. Chem. 1992, 35, 3512-3519). To elucidate the pharmacological significance of this latter binding affinity, which is also shown by quisqualic acid (3) but not by AMPA, we have now resolved Bu-HIBO via diastereomeric salt formation using the diprotected Bu-HIBO derivative 11 and the enantiomers of 1-phenylethylamine (PEA). The absolute stereochemistry of (S)-Bu-HIBO (7) (ee = 99.0%) and (R)-Bu-HIBO (8) (ee > 99.6%) were established by an X-ray crystallographic analysis of compound 15, a salt of (R)-PEA, and diprotected 8. Circular dichroism spectra of 7 and 8 were recorded. Whereas 7 (IC50 = 0.64 microM) and 8 (IC50 = 0.57 microM) were equipotent as inhibitors of CaCl2-dependent [3H]-(S)-glutamic acid binding, neither enantiomer showed significant affinity for the synaptosomal (S)-glutamic acid uptake system(s). AMPA receptor affinity (IC50 = 0.48 microM) and agonism (EC50 = 17 microM) were shown to reside exclusively in the S-enantiomer, 7. Compounds 7 and 8 did not interact detectably with kainic acid or N-methyl-D-aspartic acid (NMDA) receptor sites. Neither 7 nor 8 affected the function of the metabotropic (S)-glutamic acid receptors mGlu2 and mGlu4a, expressed in CHO cells. Compound 8 was shown also to be inactive at mGlu1 alpha, whereas 7 was determined to be a moderately potent antagonist at mGlu1 alpha (Ki = 110 microM) and mGlu5a (Ki = 97 microM). Using the rat cortical wedge preparation, the AMPA receptor agonist effect of 7 was markedly potentiated by coadministration of 8 at 21 degrees C, but not at 2-4 degrees C. These observations together indicate that the potentiation of the AMPA receptor agonism of 7 by 8 is not mediated by metabotropic (S)-glutamate receptors but rather by the CaCl2-dependent (S)-glutamic acid binding system, which shows the characteristics of a transport mechanism. After intravenous administration in mice, 7 (ED50 = 44 mumol/kg) was slightly more potent than AMPA (1) (ED50 = 55 mumol/kg) and twice as potent as Bu-HIBO (6) (ED50 = 94 mumol/kg) as a convulsant, whereas 8 was inactive. After subcutaneous administration in mice, Bu-HIBO (ED50 = 110 mumol/kg) was twice as potent as AMPA (ED50 = 220 mumol/kg) as a convulsant. Since 7 and Bu-HIBO (EC50 = 37 microM) are much weaker than AMPA (EC50 = 3.5 microM) as AMPA receptor agonists in vitro, the presence of a butyl group in the molecules of Bu-HIBO and 7 seems to facilitate the penetration of these compounds through the blood-brain barrier.lld:pubmed
pubmed-article:9526567pubmed:languageenglld:pubmed
pubmed-article:9526567pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:citationSubsetIMlld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9526567pubmed:statusMEDLINElld:pubmed
pubmed-article:9526567pubmed:monthMarlld:pubmed
pubmed-article:9526567pubmed:issn0022-2623lld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:Krogsgaard-La...lld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:EberlJJlld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:MadsenUUlld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:BrehmLLlld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:ChristensenI...lld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:JohansenT NTNlld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:Bräuner-Osbor...lld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:DidriksenMMlld:pubmed
pubmed-article:9526567pubmed:authorpubmed-author:SøbyK KKKlld:pubmed
pubmed-article:9526567pubmed:issnTypePrintlld:pubmed
pubmed-article:9526567pubmed:day12lld:pubmed
pubmed-article:9526567pubmed:volume41lld:pubmed
pubmed-article:9526567pubmed:ownerNLMlld:pubmed
pubmed-article:9526567pubmed:authorsCompleteYlld:pubmed
pubmed-article:9526567pubmed:pagination930-9lld:pubmed
pubmed-article:9526567pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:meshHeadingpubmed-meshheading:9526567-...lld:pubmed
pubmed-article:9526567pubmed:year1998lld:pubmed
pubmed-article:9526567pubmed:articleTitleExcitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)propionic acid.lld:pubmed
pubmed-article:9526567pubmed:affiliationPharmaBiotec Research Center, Department of Medicinal Chemistry, Royal Danish School of Pharmacy, 2 Universitetsparken, Copenhagen, Denmark.lld:pubmed
pubmed-article:9526567pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9526567pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9526567pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:9526567lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9526567lld:pubmed